Accuracy of immunohistochemistry in evaluation of malignant pleural and peritoneal effusions

Polish Journal of Pathology

Volumn 62, Issue 2, 2011, Pages 95-100

  Ensani, Fereshteh ^a   Nematizadeh, Farnaz ^a   Irvanlou, Giti ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Immunohistochemistry; Peritoneal effusion; Pleural effusion

Indexed keywords

BIOLOGICAL MARKER; CALBINDIN; CALRETININ; DIAGNOSTIC AGENT; MOC 31 MONOCLONAL ANTIBODY, HUMAN; MOC-31 MONOCLONAL ANTIBODY, HUMAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2-40; MUCIN 1; TUMOR MARKER; WT1 PROTEIN;

ARTICLE; ASCITES FLUID; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PLEURA EFFUSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ASCITIC FLUID; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUCIN-1; PLEURAL EFFUSION, MALIGNANT; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 84860395659     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol 2006; 30: 878-882.
2. Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol 2004; 31: 246-254.
3. Bedrossian CW. Diagnostic problems in serous effusions. Diagn Cytopathol 1998; 19: 131-137.
4. Saleh HA, El-Fakharany M, Makki H, et al. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis. Diagn Cytopathol 2009; 37: 324-332.
5. Kim JH, Kim GE, Choi YD, et al. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks. Diagn Cytopathol 2009; 37: 258-261.
6. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? Arch Pathol Lab Med 2008; 132: 23-28.
7. Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 2007; 109: 933-938.
8. Politi E, Kandaraki C, Apostolopoulou C, et al. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005; 32: 151-155.
9. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48: 223-232.
10. Lozano MD, Panizo A, Toledo GR, et al. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer 2001; 93: 68-72.
11. Shidham V, Atkinson B. Immunocytochemistry of effusions-processing and commonly used immunomarkers. In: Cytopathologic diagnosis of serous fluids. Shidham V (ed.). 1st ed. Elsevier 2007; 237-257.
12. King J, Thatcher N, Pickering C, Hasleton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006; 49: 561-568.